Clinical Trial Participant Diversity: The Gaps and How Logistics Strategies Can Solve Them

By Clinical Trial Management, Cold Chain, Packaging & Distribution, Supply Chain, Uncategorized No Comments

The success of a clinical trial often depends on attracting the appropriate participants so that the sample reflects the general population. But how to ensure that this is the case? We’ve found some of the major problems with clinical trial diversity and how to solve them. Who is Represented? Studies indicate that many trials under-represent women, people of colour, and…

Read More

Challenges Facing Rare Disease Clinical Trials

By Clinical Trial Management, Cold Chain, Outsourcing, Packaging and Distribution, Supply Chain No Comments

The USA Orphan Drug Act of 1983 created incentives for pharmaceutical companies to research and create new drug therapies for rare diseases. These incentives include tax breaks, exclusive marketing rights, unique research grants and fast-tracked FDA review processes. As a result, the clinical costs associated with the development of an orphan drug are less than those associated with non-orphan drugs1….

Read More

6 Things That Differ Between Industry-Initiated and Academic Clinical Trials

By Clinical Trial Management, Health Care Research No Comments

Clinical trials are fundamental to testing new medicine, investigating existing medicine and improving healthcare. Most research protocols are either designed by researchers employed by the pharmaceutical/ medical device company or investigators from academic institutions. Here are six things that distinguish industry clinical trials from academic clinical trials: Funding – Industry-initiated clinical trials are financially supported by the industry. The primary…

Read More

3 Packaging Decisions You Can Make to Improve Clinical Trial Compliance

By Clinical Trial Management, Outsourcing, Packaging and Distribution No Comments

Study non-adherence is an ongoing problem surrounding clinical trials. Noncompliance drives up research costs and increases the time it takes new medicines to make it to the market. One study suggests that costs associated with noncompliance are as high as $1.5 billion by the time the investigational product (IP) is fully developed 1. Considerate IP packaging is one way researchers…

Read More